insights_auto
Pourquoi 4142 a-t-elle baissé de 6,62%?
Approfondirchevron_right
4142:TPE
Adimmune Corp
14,80 TWD
arrow_downward
-6,62%(-1,05) 1J
20 nov., 13:30:09 UTC+8 · TWD
search
Tous les symboles
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour 4142...
Ouverture
15,75 TWD
Élevé
15,75 TWD
Faible
14,80 TWD
Cap. boursière
6,36 Md
Vol. moyen
1,13 M
Volume
1,63 M
Ratio cours/bénéfice
85,76
+ haut sur 1 an
21,50 TWD
+ bas sur 1 an
14,80 TWD
BPA
0,17 TWD
Actions en circulation
235,29 M
Nombre d'employés
564
Ouverture
15,75 TWD
Élevé
15,75 TWD
Faible
14,80 TWD
Cap. boursière
6,36 Md
Vol. moyen
1,13 M
Volume
1,63 M
Ratio cours/bénéfice
85,76
+ haut sur 1 an
21,50 TWD
+ bas sur 1 an
14,80 TWD
BPA
0,17 TWD
Actions en circulation
235,29 M
Nombre d'employés
564
Articles
Sources : Web et partenaires du secteur de l'information
Fortune
·
il y a 1 heure
Stock market correction? This chief investment officer sees the S&P 500 soaring 45% to 10,000
24/7 Wall St.
·
il y a 4 heures
The S&P 500 Is Now Below Every Wall Street Year-End Target for 2026
Yahoo Finance
·
il y a 6 heures
T-Bills Are Beating the Nasdaq, S&P 500 and Dow This Year
The Coin Republic
·
il y a 7 heures
Effondrement du S&P 500 : des pertes estimées à 6 000 milliards de dollars après sept jours de baisse
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
À propos de Adimmune Corp